MedTrace Logo

A Study of Pridopidine (ACR16) for the Treatment of Participants With Huntington's Disease

NCT00724048 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 227

Last updated 2023-08-31

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine if ACR16 is effective and safe in the symptomatic treatment of Huntington's Disease.

Conditions

  • Huntington Disease

Interventions

DRUG

ACR16

ACR16 will be administered per dose and schedule specified in the arm description.

OTHER

Placebo

Placebo matching to ACR16 will be administered per schedule specified in the arm description.

Sponsors & Collaborators

  • Teva Branded Pharmaceutical Products R&D, Inc.

    lead INDUSTRY

Principal Investigators

  • Teva Medical Expert · Teva Branded Pharmaceutical Products R&D, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-10-24
Primary Completion
2010-07-26
Completion
2010-07-26

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00724048 on ClinicalTrials.gov